TY - JOUR
T1 - Multi-center analysis of machine-learning predicted dose parameters in brachytherapy for cervical cancer
AU - Reijtenbagh, Dominique
AU - Godart, Jérémy
AU - de Leeuw, Astrid
AU - Seppenwoolde, Yvette
AU - Jürgenliemk-Schulz, Ina
AU - Mens, Jan Willem
AU - Nout, Remi
AU - Hoogeman, Mischa
N1 - Funding Information:
This work was in part funded by a research grant of Elekta AB (Stockholm, Sweden). The funders had no role in study design, data collection and analysis, and decisions on preparation of the manuscript. Erasmus MC Cancer Institute also has research collaborations with Accuray Inc, Sunnyvale, USA and Varian Medical Systems Particle Therapy GmbH & Co. KG, Troisdorf, Germany. Professor Hoogeman reports a membership of the advisory board Accuray, Sunnyvale, USA.
Funding Information:
This work was in part funded by a research grant of Elekta AB (Stockholm, Sweden). The funders had no role in study design, data collection and analysis, and decisions on preparation of the manuscript. Erasmus MC Cancer Institute also has research collaborations with Accuray Inc, Sunnyvale, USA and Varian Medical Systems Particle Therapy GmbH & Co. KG, Troisdorf, Germany. Professor Hoogeman reports a membership of the advisory board Accuray, Sunnyvale, USA.
Publisher Copyright:
© 2022 The Authors
Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.
PY - 2022/5
Y1 - 2022/5
N2 - Background and purpose: Image-guided adaptive brachytherapy (IGABT) is a key component in the treatment of cervical cancer, but the nature of the clinical workflow makes it vulnerable to suboptimal plans, as the theoretical optimal plan depends heavily on organ configuration. Patient anatomy-based quality-assurance (QA) with overlap volume histograms (OVHs) is a promising tool to detect such suboptimal plans, and in this analysis its suitability as a multi-institutional clinical QA tool is investigated. Materials and methods: A total of 223 plans of 145 patients treated in accordance with the current state-of-the-art IGABT protocols from UMC Utrecht (UMCU) and Erasmus MC (EMC) were included. Machine-learning models were trained to predict dose D2cm3 to bladder, rectum, sigmoid and small bowel with the help of OVHs. For this strategy, points are sampled on the organs-at-risk (OARs), and the distances of the sampled points to the target are computed and combined in a histogram. Machine-learning models can then be trained to predict dose-volume histograms (DVHs) for unseen data. Single-center model robustness to needle use and applicator type and multi-center model translatability were investigated. Performance of models was assessed by the difference between planned (clinical) and predicted D2cm3 values. Results: Intra-validation of UMCU data demonstrated OVH model robustness to needle use and applicator type. The model trained on UMCU data was found to be robust within the same protocol on EMC data, for all investigated OARs. Mean squared error between planned and predicted D2cm3 values of OARs ranged between 0.13 and 0.40 Gy within the same protocol, indicating model translatability. For the former protocol cohort of Erasmus MC large deviations were found between the planned and predicted D2cm3 values, indicating plan deviation from protocol. Mean squared error for this cohort ranged from 0.84 to 4.71 Gy. Conclusion: OVH-based models can provide a solid basis for multi-institutional QA when trained on a sufficiently strict protocol. Further research will quantify the model's impact as a QA tool.
AB - Background and purpose: Image-guided adaptive brachytherapy (IGABT) is a key component in the treatment of cervical cancer, but the nature of the clinical workflow makes it vulnerable to suboptimal plans, as the theoretical optimal plan depends heavily on organ configuration. Patient anatomy-based quality-assurance (QA) with overlap volume histograms (OVHs) is a promising tool to detect such suboptimal plans, and in this analysis its suitability as a multi-institutional clinical QA tool is investigated. Materials and methods: A total of 223 plans of 145 patients treated in accordance with the current state-of-the-art IGABT protocols from UMC Utrecht (UMCU) and Erasmus MC (EMC) were included. Machine-learning models were trained to predict dose D2cm3 to bladder, rectum, sigmoid and small bowel with the help of OVHs. For this strategy, points are sampled on the organs-at-risk (OARs), and the distances of the sampled points to the target are computed and combined in a histogram. Machine-learning models can then be trained to predict dose-volume histograms (DVHs) for unseen data. Single-center model robustness to needle use and applicator type and multi-center model translatability were investigated. Performance of models was assessed by the difference between planned (clinical) and predicted D2cm3 values. Results: Intra-validation of UMCU data demonstrated OVH model robustness to needle use and applicator type. The model trained on UMCU data was found to be robust within the same protocol on EMC data, for all investigated OARs. Mean squared error between planned and predicted D2cm3 values of OARs ranged between 0.13 and 0.40 Gy within the same protocol, indicating model translatability. For the former protocol cohort of Erasmus MC large deviations were found between the planned and predicted D2cm3 values, indicating plan deviation from protocol. Mean squared error for this cohort ranged from 0.84 to 4.71 Gy. Conclusion: OVH-based models can provide a solid basis for multi-institutional QA when trained on a sufficiently strict protocol. Further research will quantify the model's impact as a QA tool.
KW - Cervical cancer
KW - DVH prediction
KW - Image guided brachytherapy
KW - Overlap volume histogram
KW - Radiotherapy Dosage
KW - Radiotherapy Planning, Computer-Assisted/methods
KW - Uterine Cervical Neoplasms/radiotherapy
KW - Humans
KW - Brachytherapy/methods
KW - Female
KW - Organs at Risk
KW - Machine Learning
UR - http://www.scopus.com/inward/record.url?scp=85128207322&partnerID=8YFLogxK
U2 - 10.1016/j.radonc.2022.02.022
DO - 10.1016/j.radonc.2022.02.022
M3 - Article
C2 - 35219799
AN - SCOPUS:85128207322
SN - 0167-8140
VL - 170
SP - 169
EP - 175
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
ER -